產(chǎn)品分類導(dǎo)航
(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽
(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽
(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽

(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽

更新時(shí)間:2024-11-12

價(jià)格:  
CAS號: 1223405-08-0
藥典: 中國藥典
級別: 醫(yī)藥級別
立即詢盤
收藏
產(chǎn)品詳情
產(chǎn)品包裝規(guī)格: 純度99%
最低訂購量: 1千克
供貨能力: 100
付款方式: 款到發(fā)貨
交貨周期: 3天
主要銷售市場: 北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
是否提供樣品:
樣品政策: 僅供研發(fā)
產(chǎn)品描述:

商品名稱 
CAS號 1223405-08-0
分子式 C21H24F2N6O6S
分子量 526.51400
LogP 3.45140
PSA 168.98000
產(chǎn)品描述:loxo-101 is a small molecule that was designed to block the atp binding site of the trk family of receptors, with 2 to 20 nm cellular potency against the trka, trkb, and trkc kinases. ic50 value: 2 - 20 nm target: trka/b/c in vitro: loxo-101 is an orally administered inhibitor of the trk kinase and is highly selective only for the trk family of receptors. loxo-101 is evaluated for off-target kinase enzyme inhibition against a panel of 226 non-trk kinases at a compound concentration of 1,000 nm and atp concentrations near the km for each enzyme. in the panel, loxo-101 demonstrates greater than 50% inhibition for only one non-trk kinase (tnk2 ic50, 576 nm). measurement of proliferation following treatment with loxo-101 demonstrates a dose-dependent inhibition of cell proliferation in all three cell lines. the ic50 is less than 100 nm for cuto-3.29 and less than 10 nm for km12 and mo-91, consistent with the known potency of this drug for the trk kinase family. [1] loxo-101 demonstrates potent and highly-selective inhibition of trka, trkb, and trkc over other kinase- and non-kinase targets. loxo-101 is a potent, atp-competitive trk inhibitor with ic50s in low nanomolar range for inhibition of all trk family members in binding and cellular assays, with 100x selectivity over other kinases. [2] in vivo: athymic nude mice injected with km12 cells are treated with loxo-101 orally daily for 2 weeks. dose-dependent tumor inhibition is observed, demonstrating the ability of this selective compound to inhibit tumor growth in vivo. 
 

安徽海康藥業(yè)股份有限公司
注冊資本不愿意公開
公司地址
安徽省安慶市大觀區(qū)環(huán)城西路21號
聯(lián)系人
聯(lián)系電話
聯(lián)系手機(jī)
查看聯(lián)系方式
快速詢盤
詢盤主題
請輸入詢盤主題
詢盤信息
請輸入詢盤信息
滑動(dòng)驗(yàn)證
請完成滑塊驗(yàn)證
快速發(fā)送詢盤
CPHI制藥在線為您找到(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽 價(jià)格、(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽 詳細(xì)參數(shù)、(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽 相關(guān)產(chǎn)品、(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽 供應(yīng)商等信息,想了解當(dāng)前(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基]-3-羥基-1-吡咯烷甲酰胺硫酸鹽 最新報(bào)價(jià),請聯(lián)系安徽??邓帢I(yè)股份有限公司。
2006-2024 上海博華國際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號-57